<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124333">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01847573</url>
  </required_header>
  <id_info>
    <org_study_id>HALO-DMD-01</org_study_id>
    <secondary_id>HALO</secondary_id>
    <nct_id>NCT01847573</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halo Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halo Therapeutics, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to test the safety and tolerability of different,
      increasing doses of an experimental medication called HT-100 in boys and young men with
      Duchenne muscular dystrophy (DMD).  The study medication, HT-100, is a medicine that may
      help promote healthy muscle regeneration, diminish inflammation and the resulting damage to
      muscle, and decrease the scar tissue that forms in the muscles of children with DMD. In this
      study, pharmacokinetic sampling, or measurements of the amount of HT-100 in the bloodstream
      will also be taken.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    FDA placed the protocol on clinical hold while new data are evaluated. Enrolled subjects are
    not taking HT-100. Clinic visits are continuing per protocol.
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of administering single and multiple ascending doses of HT-100 in DMD boys</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety profile by review of adverse events (AEs), physical examination findings, clinical laboratory test results, and other diagnostic testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic plasma profile of halofuginone after single and multiple dose administration of HT-100 in DMD boys</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Halofuginone plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of administering multiple ascending doses of HT-100 in DMD boys over 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety profile by review of AEs, physical examination findings, clinical laboratory test results, and other diagnostic testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early pharmacodynamic signals of HT-100 after 4 weeks of continuous dosing in DMD boys</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacodynamic measures relevant to DMD pathology:
Pulmonary function
Motor function
Muscle composition
Biochemical and imaging markers</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: HT-100 tablet, Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 1
Multiple dose administration: Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: HT-100 tablet, Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 2
Multiple dose administration: Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: HT-100 tablet, Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 3
Multiple dose administration: Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: HT-100 tablet, Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 4
Multiple dose administration: Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: HT-100 tablet, Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 5
Multiple dose administration: Dose 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HT-100</intervention_name>
    <description>May be administered in either fed or fasted state</description>
    <arm_group_label>Cohort 1: HT-100 tablet, Dose 1</arm_group_label>
    <arm_group_label>Cohort 2: HT-100 tablet, Dose 2</arm_group_label>
    <arm_group_label>Cohort 3: HT-100 tablet, Dose 3</arm_group_label>
    <arm_group_label>Cohort 4: HT-100 tablet, Dose 4</arm_group_label>
    <arm_group_label>Cohort 5: HT-100 tablet, Dose 5</arm_group_label>
    <other_name>halofuginone hydrobromide delayed-release tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Ambulatory or non-ambulatory

          -  Diagnosis of DMD with confirmation of minimal to no dystrophin

          -  Corticosteroid naive or on therapy for at least 12 months (stable dose and regimen)

        Main Exclusion Criteria:

          -  Recent, substantial change in use of cardiac medications or medications affecting
             muscle function

          -  Inability to undergo magnetic resonance imaging (MRI)

          -  Significantly compromised cardio-respiratory function

          -  Prior treatment with another investigational product in past 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana M. Escolar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Halo Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute, Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.halotherapeutics.com/</url>
    <description>Sponsor company website</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>halofuginone hydrobromide</keyword>
  <keyword>anti-fibrotic</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>muscle regeneration</keyword>
  <keyword>protein synthesis inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Protein Synthesis Inhibitors</mesh_term>
    <mesh_term>Halofuginone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
